The Healthline report leans on a 2025 narrative review and a 2022 observational analysis to suggest watermelon consumption could cut cardiovascular risk via L-citrulline, lycopene, and potassium. Narrative reviews rank low on evidence hierarchies and lack the randomization or blinding of RCTs; the cited 2022 work appears to draw from small cohorts (n<100) without reported conflict-of-interest disclosures. Two stronger studies fill critical gaps. Figueroa et al. (2019, Nutrients) ran a double-blind crossover RCT (n=27 adults with prehypertension) showing 6 weeks of watermelon extract lowered aortic systolic pressure by 5–6 mmHg versus placebo, yet the effect vanished after washout, indicating acute rather than structural change. A 2023 meta-analysis in the American Journal of Hypertension pooled eight trials (total n=312) and found consistent but modest diastolic reductions (-2.7 mmHg) only in participants already showing cardiometabolic risk; no hard endpoints such as myocardial infarction were measured. Original coverage missed dose-response data—most benefits appeared at intakes equivalent to 2–3 cups daily—and overlooked seasonal availability plus glycemic load concerns for diabetics. Patterns across trials suggest synergy with overall DASH-style diets, not isolated swaps. Until larger, multi-year RCTs track events, watermelon remains a low-risk adjunct rather than a proven preventive.